Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial

Valérie Fonteyne, Guy Soete, Stefano Arcangeli, Wilfried De Neve, Bernard Rappe, Guy Storme, Lidia Strigari, Giorgio Arcangeli, Gert De Meerleer

Research output: Contribution to journalArticlepeer-review


Purpose: To report late gastrointestinal (GI) and genitourinary (GU) toxicity, biochemical and clinical outcomes, and overall survival after hypofractionated radiation therapy for prostate cancer (PC). Methods and Materials: Three institutions included 113 patients with T1 to T3N0M0 PC in aphase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Late toxicity was scored using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms. Biochemical outcome was reported according to the Phoenix definition for biochemical failure. Results: The incidence of late GI and GU toxicity was low. The 3-year actuarial risk of developing late GU and GI toxicity of grade ≥2 was 13% and 8% respectively. Five-year biochemical non-evidence of disease (bNED) was 94%. Risk group, T stage, and deviation from planned hormone treatment were significant predictive factors for bNED. Deviation from hormone treatment remained significant in multivariate analysis. Five-year clinical non evidence of disease and overall survival was 95% and 91% respectively. No patient died from PC. Conclusions: Hypofractionated high-dose radiation therapy is a valuable treatment option for patients with PC, with excellent biochemical and clinical outcome and low toxicity.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number4
Publication statusPublished - Nov 15 2012

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research


Dive into the research topics of 'Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial'. Together they form a unique fingerprint.

Cite this